Phage Therapy Market: Size, Trends & Forecasts (2019 Edition)

Table of Contents

1. Executive Summary

2. Introduction
2.1 Phages: An Overview
2.2 Phage Working Mechanism
2.3 Difference between Phages and Antibiotics
2.4 Phage Therapy: An Overview
2.5 Phage Therapy: Brief History
2.6 Limitations of Phage Therapy and its Address
2.7 Global Phage Therapy Market: An Overview
2.8 Global Phage Therapy Market Segments

3. Global Phage Market Analysis
3.1 Global Phage Market: An Analysis
3.1.1 Global Phage Market by Value

4. Global Phage Therapy Market Analysis
4.1 Global Phage Therapy Market: Market Opportunity Analysis
4.1.1 S. aureus Bacteremia
4.1.2 P. aeruginosa Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP)
4.1.3 P. aeruginosa Cystic Fibrosis

5. The US Phage Therapy Market Analysis
5.1 The US Phage Therapy Market: An Analysis
5.1.1 The US AP-SA01 Phage Market for Bacteremia by Value
5.1.2 The US AP-PA02 Phage Market for HAP/VAP by Value
5.1.3 The US AP-PA02 Phage Market for CF Patients by Value

6. Market Dynamics
6.1 Growth Drivers
6.1.1 Considerable Spike in Antibiotic Resistance
6.1.2 Improving Regulatory Scenario
6.1.3 Demonstration of Improved Efficacy
6.1.4 Excellent Safety Profile
6.2 Challenges
6.2.1 Vulnerability to Security Breaches
6.3 Market Trends
6.3.1 Phage Product Launch in Pipeline
6.3.2 Phage Endolysins
6.3.3 Technological Advancements
6.3.4 Fresh Research on Revival of Phage Therapy for Treatment of Cholera
6.3.5 Bacteriophage T4 Nanoparticle-Based Dual Vaccine

7. Competitive Landscape
7.1 Global Phage Therapy Market: Players Analysis

8. Company Profiles
8.1 Armata Pharmaceuticals Inc.
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategy
8.2 Intralytix Inc.
8.2.1 Business Overview
8.2.2 Business Strategy
8.3 Adaptive Phage Therapeutics, Inc.
8.3.1 Business Overview
8.3.2 Business Strategy
8.4 Pherecydes Pharma
8.4.1 Business Overview
8.4.2 Business Strategy
8.5 Locus Biosciences Inc.
8.5.1 Business Overview
8.5.2 Business Strategy

List of Figures
Figure 1: Global Phage Therapy Market Segments
Figure 2: Global Phage Market by Value; 2017-2018 (US$ Million)
Figure 3: Global Phage Market by Value; 2019-2023 (US$ Million)
Figure 4: The US AP-SA01 Phage Market for Bacteremia by Value; 2025-2030 (US$ Million)
Figure 5: The US AP-PA02 Phage Market for HAP/VAP by Value; 2025-2030 (US$ Million)
Figure 6: The US AP-PA02 Phage Market for CF Patients by Value; 2025-2030 (US$ Million)
Figure 7: Armata Pharmaceuticals Revenues 2014-2018 (US$ Thousands)

List of Tables
Table 1: Phages Versus Antibiotics
Table 2: Limitations of Phage Therapy and Its Address
Table 3: Phage Therapy Market on the Basis of Applications
Table 4: Phage Product in Pipeline
Table 5: Therapeutic Phage Industry- Clinical Stage Phage Companies
Table 6: Therapeutic Phage Industry- Preclinical Stage Phage Companies
Table 7: Therapeutic Phage Industry-Phage Endolysins
Table 8: Intralytix Bacteriophage Product Portfolio

Executive Summary

A phage (also known as bacteriophages) are viruses that are engineered with the aim to infect bacteria and neutralize them through mechanisms that happen to be very different from those of antibiotics. Phage therapy is the therapeutic use of these phages for the treatment of pathogenic bacterial infections such as pneumonia and bacteremia.

The global phage therapy market can be segmented on the basis of mode of administration and application. On the basis of mode of administration, the market can be split into oral, rectal, local (skin, eye, ear, nasal mucosa etc.) in tampons, rinses and creams and intravenous. On the basis of application, the market can be sub segmented into human medicine, dentistry, veterinary science, and agriculture.

The global phage therapy market possesses significant opportunities in the treatment of diseases like Bacteremia and Pneumonia. The growth of the phage therapy market is supported by various growth drivers such as considerable spike in antibiotic resistance, improving regulatory scenario, demonstration of improved efficacy and excellent safety profile. Tackling material disruption of targeted phage therapies and bacteriophage product candidates in the event of security breeches is a major challenge for the players operating within the market.

Phage product launch in pipeline such as AP-SA01 (cocktail of three natural (unmodified) lytic phages developed for the treatment of S. aureus Bacteremia (SAB) blood stream infection) and AP-PA02 (cocktail of four genetically-modified/synthetic phages specific for Pseudomonas aeruginos focusing on the treatment of hospital-acquired/ventilator-associated Pneumonia (HAP/VAP) and/or cystic fibrosis (CF) Pneumonia), phage endolysins, technological advancements, fresh research on revival of phage therapy for the treatment of Cholera and bacteriophage T4 nanoparticle based dual vaccine are some of the latest trends existing in the market that have been captured in this report.

Companies Mentioned

• Adaptive Phage Therapeutics Inc.
• Armata Pharmaceuticals Inc.
• Intralytix Inc.
• Locus Biosciences Inc.
• Pherecydes Pharma